ABIONYX Pharma SA (ABNX) Stock Statistics & Valuation Metrics

ABIONYX Pharma SA has a market cap or net worth of €114.68M. The enterprise value is €42.98M.

ABIONYX Pharma SA has 34,931,010 shares outstanding. The number of shares has decreased by -2.65% in one year.

ABIONYX Pharma SA’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -34.21%.

The current PE Ratio of ABIONYX Pharma SA is ―. ABIONYX Pharma SA’s PEG ratio is ―.

In the last 12 months, ABIONYX Pharma SA had revenue of 4.60M and earned -4.40M in profits. Earnings per share was -0.14.

In the last 12 months, operating cash flow was -3.60M and capital expenditures 0.00, giving a free cash flow of -3.60M billion.

ABIONYX Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

ABIONYX Pharma SA upcoming earnings date is Mar 17, 2026, During Market Hours (Confirmed).

ABIONYX Pharma SA as a current ratio of 1.58, with Debt / Equity ratio of 37.14%

In the past 12 months, ABIONYX Pharma SA has paid -1.07M in taxes.

ABIONYX Pharma SA EV to EBITDA ratio is -9.15, with an EV/FCF ratio of -11.01.

ABIONYX Pharma SA has €3.23M in cash and marketable securities with €2.76M in debt, giving a net cash position of €478.00K billion.

Gross margin is 18.96%, with operating margin of -97.83%, and net profit margin of -95.65%.

The average price target for ABIONYX Pharma SA is €2.00, which is 11.43% higher than the current price. The consensus rating is Hold